Post by
toade1313 on Apr 02, 2024 5:16pm
Hoping To Hear Tomorrow
1. What caused the delay of submitting the preBTD in 1st quarter? What must happen for it to be submitted in 2nd quarter?
2. Why are we still at 63 patients?
Comment by
Dumbeldorfwhite on Apr 02, 2024 5:20pm
3. Did we just give up on virus research 4. Where is the GBM pre clinical data and why they chose transferrin over the better suited 1633 and why is it so far behind 5. who was responsible for underdosing 12 patients
Comment by
Alamir1111 on Apr 02, 2024 5:47pm
Tld1633 I remember that 1000 times more potent .Do we have a patent on that?
Comment by
Dumbeldorfwhite on Apr 02, 2024 6:36pm
Sure but they are so far behind using it for anything
Comment by
skier59 on Apr 02, 2024 6:38pm
Actually, those are very good questions I'd like to know about, being as I'm an investor of over 10 years and have yet to see any real appreciation in my INVESTMENT !
Comment by
Dumbeldorfwhite on Apr 02, 2024 7:53pm
Skier didn't they try and sue you too lol
Comment by
DeathXray33 on Apr 02, 2024 8:39pm
It's actually a Billion times more potent. A BILLION. Less than a gram for a batch. Extremely powerful. It's in a previous news release.
Comment by
Dumbeldorfwhite on Apr 02, 2024 9:45pm
So why wasn't this all mighty compound chosen for the GBM? I mean they had to do the preclinical work anyways, why not use the "better compound". Crazy the company doesn't address these things
Comment by
tdon1229 on Apr 03, 2024 9:43am
Just a reminder that patients are not included in the count until they are screened, qualified, waited for treatment, received treatment, examined post treatment, and initial reported by their PI.